Use of Voraxaze® Leads to Reduced Length of Stay and Reduced Mortality Rates1
In a retrospective study of Medicare patients with cancer, patients treated with Voraxaze® had all of the following benefits compared to nonglucarpidase patients treated with dialysis (dialysis+) and nonglucarpidase patients with or without dialysis treatment (dialysis+/-), respectively1*:
*Utilizing Medicare inpatient claims data between 2010 and 2017, investigators compared outcomes and healthcare resource utilization between patients treated
with Voraxaze® (n=30) and patients not treated with Voraxaze® (n=701), all of whom had experienced AKI secondary to inpatient chemotherapy.
- Shorter mean hospital length of stay (14.7 days vs 40.2 days and 21.9 days)
- Shorter mean ICU length of stay (4.0 days vs 18.2 days in the dialysis+ group)
- Lower inpatient mortality rates (3.3% vs 50.6% and 20.8%)
- Lower 90-day mortality rates (16.7% vs 58.6% and 37.6%)